Next Article in Journal
Epigenetic Regulators of White Adipocyte Browning
Next Article in Special Issue
Thermal Stability Changes in Telomeric G-Quadruplex Structures Due to N6-Methyladenine Modification
Previous Article in Journal
Epigenetic Regulation of Epidermal Differentiation
Previous Article in Special Issue
Epigenetics of Skeletal Muscle-Associated Genes in the ASB, LRRC, TMEM, and OSBPL Gene Families
Open AccessReview

The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma

1
Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA
2
Graduate Program in Genetics & Epigenetics, UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Received: 13 December 2020 / Revised: 31 December 2020 / Accepted: 3 January 2021 / Published: 5 January 2021
(This article belongs to the Special Issue Recent Advances in Biological Methylation)
Arginine methylation is an essential post-translational modification (PTM) deposited by protein arginine methyltransferases (PRMTs) and recognized by Tudor domain-containing proteins. Of the nine mammalian PRMTs, PRMT5 is the primary enzyme responsible for the deposition of symmetric arginine methylation marks in cells. The staphylococcal nuclease and Tudor domain-containing 1 (SND1) effector protein is a key reader of the marks deposited by PRMT5. Both PRMT5 and SND1 are broadly expressed and their deregulation is reported to be associated with a range of disease phenotypes, including cancer. Hepatocellular carcinoma (HCC) is an example of a cancer type that often displays elevated PRMT5 and SND1 levels, and there is evidence that hyperactivation of this axis is oncogenic. Importantly, this pathway can be tempered with small-molecule inhibitors that target PRMT5, offering a therapeutic node for cancer, such as HCC, that display high PRMT5–SND1 axis activity. Here we summarize the known activities of this writer–reader pair, with a focus on their biological roles in HCC. This will help establish a foundation for treating HCC with PRMT5 inhibitors and also identify potential biomarkers that could predict sensitivity to this type of therapy. View Full-Text
Keywords: arginine methylation; PRMT5; SND1; Tudor-SN; p100; HCC arginine methylation; PRMT5; SND1; Tudor-SN; p100; HCC
Show Figures

Figure 1

MDPI and ACS Style

Wright, T.; Wang, Y.; Bedford, M.T. The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma. Epigenomes 2021, 5, 2. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5010002

AMA Style

Wright T, Wang Y, Bedford MT. The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma. Epigenomes. 2021; 5(1):2. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5010002

Chicago/Turabian Style

Wright, Tanner; Wang, Yalong; Bedford, Mark T. 2021. "The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma" Epigenomes 5, no. 1: 2. https://0-doi-org.brum.beds.ac.uk/10.3390/epigenomes5010002

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop